Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced that its key investee, Hangzhou Aorui Biotechnology Co., Ltd. ("Aorui Bio"), has recently obtained a Class III medical device registration certificate in China. The product, named "TSPYL5, RASSF1A, DAB2IP, OTX1, PTPN18, HIST1H3G Gene Methylation Detection Kit (PCR Fluorescent Probe Method)," is designed for the qualitative detection of methylated TSPYL5, RASSF1A, DAB2IP, OTX1, PTPN18, and HIST1H3G genes in human plasma. This product is intended for clinical auxiliary diagnosis of suspected primary liver cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments